Xi'an Sonwu Biotech Co., Ltd. is one of the most professional manufacturers and suppliers of qaw039 powder in China. We warmly welcome yuo to wholesale bulk qaw039 powder for sale here from our factory. Quality products and reasonable price are available.
Basic Information
|
Items |
Specification |
|
Appearance |
White powder |
|
Purity |
≥ 99.0% |
|
MF |
C19H17F3N2O4S |
|
MW |
426.40 |
|
Powder MOQ |
10g |
|
Packaging |
Vaccum sealed foil packaging |
|
Lead time |
7~15 days |
|
OEM service |
Available |
|
In stock |
Yes |

Fevipiprant Qaw039 Powder
QAW039 powder, also known as Fevipiprant or NVP-QAW039, is an investigational oral non-steroidal anti-inflammatory compound developed by Novartis. It belongs to a class of drugs known as selective prostaglandin D2 receptor 2 (DP2-also referred to as CRTh2) antagonists. The drug is primarily intended for the treatment of asthma, specifically allergic asthma and eosinophilic asthma. Unlike traditional corticosteroids, Fevipiprant functions by selectively blocking specific inflammatory signaling pathways, rather than broadly suppressing immune activity. Furthermore, it has been investigated for use in other allergic and inflammatory conditions, including atopic dermatitis and allergic rhinitis. If you need QAW039, Xi'an Sonwu can supply it. Xi'an Sonwu is looking forward to hearing from you.
Qaw039 Powder Price
Xi'an Sonwu Biotech Co., Ltd. focuses on the supply of pharmaceutical raw materials, anti-hair loss products, peptides, weight management solutions, and plant extracts. Xi'an Sonwu are committed to providing high-quality ingredients and reliable sourcing solutions to global clients, meeting the diverse needs of the pharmaceutical, nutraceutical, cosmetic, and health industries.
Xi'an Sonwu can supply high-quality Qaw039 powder.
What we provide includes:
Raw material with a high purity level of 99%
Every batch undergoes COA and HPLC testing
Availability of both samples and bulk supplies
Support for private-label customization and global export
Qaw039 Certificate Of Analysis
|
ANALYSIS |
SPECIFICATION |
RUSULT |
|
Assay |
≥ 99.0% |
99.42% |
|
Appearance |
White powder |
Complies |
|
Residue on ignition |
≤0.1% |
0.05% |
|
Loss on drying |
≤1% |
0.26% |
|
Heavy metals |
||
|
Cd |
≤0.2ppm |
0.10ppm |
|
Pb |
≤0.2ppm |
0.05ppm |
|
As |
≤0.6ppm |
Complies |
|
Hg |
≤0.2ppm |
Complies |
|
Total bacteria count |
≤1000cfu/g |
102cfu/g |
|
Fungi |
≤100cfu/g |
33cfu/g |
|
E.Coli |
Negative |
Complies |
|
Salmonella |
Negative |
Complies |
|
Conclusion |
This product conforms to international standards |
|

How does Sonwu arrange shipping
Xi'an Sonwu provides shipping services to various regions worldwide, utilizing carriers such as specialized shipping lines, DHL, UPS, EMS, and FedEx. For shipments to the United States and Europe, for instance, we offer a specialized "door-to-door" shipping service that includes customs clearance and is duty-free; the typical transit time is approximately 15 days. When arranging shipments, we adjust the product description and the declared value to ensure a smoother delivery process for our clients.

In addition to guaranteeing product quality, the other most vital thing is that clients receive the goods smoothly. Therefore, Xi'an Sonwu offers a variety of couriers to meet different needs.

OEM Service
Xi'an Sonwu can supply high-quality Qaw039 powder.
So customers can customize the capsules they want. The items below can be supplied.
Customized capsule shells (size, color, material)
Customized bottles(size, color, material, style)
Customized packaging(vacuum foil packaging, box, drum)
Customized label(paint film, matte film, optical mask)
Fevipiprant Mechanism Of Action
Fevipiprant (QAW039, CAS No. 872365-14-5) is an orally active, non-steroidal, highly selective, reversible antagonist of the prostaglandin D2 receptor 2 (DP2), also known as CRTh2.
Its primary mechanism of action involves blocking the binding of prostaglandin D2 (PGD2) to DP2 receptors, thereby inhibiting allergic inflammation and eosinophil-mediated inflammatory responses.
1. Core Mechanism of Action
The mechanism of action can be divided into three main stages:
Step 1: PGD2 Release
During allergic or inflammatory responses, immune cells such as mast cells release prostaglandin D2 (PGD2), an important lipid mediator involved in allergic inflammation.
Step 2: DP2 Receptor Activation
PGD2 binds to DP2 (CRTh2) receptors expressed on various immune cells, promoting their recruitment and activation, including:
- Eosinophils
- Th2 cells (Type 2 helper T cells)
- ILC2 cells (Group 2 innate lymphoid cells)
- Basophils
This process also contributes to the release of inflammatory cytokines, including IL-4, IL-5, and IL-13.
Step 3: DP2 Receptor Blockade by Fevipiprant
Fevipiprant competitively binds to DP2 receptors, preventing PGD2 from activating these receptors.
As a result, it reduces inflammatory cell recruitment and activation, as well as the release of associated inflammatory mediators.
Main Pharmacological Effects
|
Pharmacological effect |
Mechanism |
|
Anti-inflammatory activity |
Inhibits PGD2-mediated inflammatory signaling |
|
Anti-allergic activity |
Blocks the DP2/CRTh2 receptor pathway |
|
Eosinophil regulation |
Reduces eosinophil recruitment and activation |
|
Cytokine regulation |
Modulates IL-4, IL-5, and IL-13-related inflammatory responses |
|
Airway inflammation regulation |
Targets Type 2 inflammatory pathways associated with asthma |
Comparison with Traditional Anti-inflammatory Drugs
|
Feature |
Fevipiprant |
Corticosteroids |
|
Drug class |
DP2 receptor antagonist |
Glucocorticoids |
|
Primary target |
DP2/CRTh2 receptor |
Glucocorticoid receptor |
|
Mechanism |
Blocks a specific inflammatory signaling pathway |
Broadly regulates inflammatory gene expression |
|
Research focus |
Allergic and eosinophilic inflammation |
Various inflammatory and immune-related conditions |
4. Clinical Development
Fevipiprant was developed primarily for the treatment of asthma and underwent several Phase II and Phase III clinical trials.
Early Phase II studies demonstrated reductions in sputum eosinophil levels, suggesting potential anti-inflammatory activity in patients with eosinophilic asthma.
However, subsequent Phase III trials failed to demonstrate sufficient clinical benefits, and its asthma development program was discontinued.
Fevipiprant is not currently an approved asthma medication.
5. Potential Research Applications
Fevipiprant has been investigated in the following research areas:
Asthma Research: Investigating DP2 receptor inhibition in allergic and eosinophilic asthma.
Allergic Inflammation: Studying PGD2-mediated inflammatory responses.
Eosinophilic Inflammation: Exploring the regulation of eosinophil recruitment and activation.
Immune Signaling: Investigating the DP2/CRTh2 signaling pathway and its role in Type 2 immune responses.
Inflammatory Diseases: Exploring the potential role of DP2 receptor antagonism in other allergic and inflammatory conditions.
Fevipiprant Hair Loss
Hair loss, especially androgenetic alopecia (AGA), remains an important area of dermatological research. Beyond hormonal and genetic factors, scientists have also been investigating the role of prostaglandins and their influence on hair follicle activity.
One particularly interesting research direction involves Prostaglandin D2 (PGD2), a lipid mediator that has been associated with hair growth inhibition.
The PGD2 Connection in Hair Loss Research
A 2012 study published in Science Translational Medicine reported elevated PGD2 levels in bald scalp tissue compared with hair-bearing scalp tissue in men with androgenetic alopecia.
The study also found that PGD2 could inhibit hair growth in cultured human hair follicles and experimental animal models. These findings helped establish the PGD2 signaling pathway as an area of interest in hair follicle research.
Why Has Fevipiprant Attracted Attention?
The growing interest in the PGD2 pathway has encouraged researchers to explore compounds that interact with its associated receptors.
Fevipiprant is of interest because of its relationship with DP2 receptor signaling. This makes it relevant to scientific discussions surrounding PGD2-related pathways and their potential involvement in hair follicle regulation.
Rather than focusing exclusively on traditional hormonal approaches to hair loss, this research direction offers another perspective on the molecular factors that may influence the hair growth cycle.
Current Research Perspectives
Although the PGD2-DP2 pathway has attracted attention in hair loss research, its potential therapeutic applications remain under investigation.
It is also important to distinguish Fevipiprant from other DP2 receptor antagonists. For example, Setipiprant has been evaluated in a Phase IIa clinical trial for male androgenetic alopecia. However, the study did not demonstrate statistically significant improvements in hair growth compared with placebo.
These findings highlight the complexity of translating molecular research into effective hair loss treatments.
Future Research Potential
Understanding the relationship between prostaglandin signaling and hair follicle biology may help expand scientific knowledge of androgenetic alopecia.
Fevipiprant represents an interesting compound in the broader field of DP2 receptor research. Further studies are needed to establish whether its pharmacological properties could have any meaningful application in hair follicle research.
Factory
1. Xi'an Sonwu has a factory with sufficient stock. In addition, Xi'an Sonwu has a clean and tidy production department with advanced equipment. Under the company's leadership, researchers continue to develop new products to meet customers' needs.
2. Xi'an Sonwu has advanced testing equipment and professional testing personnel, all of which show that Xi'an Sonwu aims to provide accurate and effective data and good service.

FAQ
1. How to inquire?
We can be reached by phone, email, or social media.
2. How do you guarantee the quality of products?
Each batch must be tested, and COA can be supplied to customers. Additionally, all the products pass the test: HPLC, UV, GC, TLC, etc. We cooperate with third parties as well, like SGS.
3. How do you pack and store?
Pack: Use sealed export-grade drums and vacuum-sealed foil packaging, or pack the goods according to customers' needs.
Storage: You can keep it in a dry and cool place and make it avoid sunlight.
If you want to know about the Noopept capsules, you can contact Xi'an Sonwu. Click the email, and then you get high-quality GVS-111 capsule and powder.
Email: sales@sonwu.com
Hot Tags: qaw039 powder, China, suppliers, manufacturers, factory, wholesale, buy, price, bulk, pure, raw, supply, for sale












